3,675 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Dohj LLC

Dohj LLC purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 3,675 shares of the biotechnology company's stock, valued at approximately $951,000.

Several other institutional investors have also added to or reduced their stakes in the company. OFI Invest Asset Management acquired a new position in shares of Biogen during the 3rd quarter worth approximately $26,000. Gladius Capital Management LP bought a new position in Biogen during the 3rd quarter worth $28,000. KB Financial Partners LLC raised its holdings in Biogen by 105.1% in the 3rd quarter. KB Financial Partners LLC now owns 121 shares of the biotechnology company's stock valued at $31,000 after acquiring an additional 62 shares in the last quarter. CVA Family Office LLC bought a new stake in shares of Biogen during the 4th quarter valued at $36,000. Finally, Baker Avenue Asset Management LP grew its holdings in shares of Biogen by 215.5% during the 3rd quarter. Baker Avenue Asset Management LP now owns 183 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 125 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 262 shares of Biogen stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $221.23, for a total value of $57,962.26. Following the completion of the sale, the insider now directly owns 4,886 shares of the company's stock, valued at $1,080,929.78. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Biogen news, insider Priya Singhal sold 262 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $221.23, for a total value of $57,962.26. Following the transaction, the insider now owns 4,886 shares in the company, valued at $1,080,929.78. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Eric K. Rowinsky acquired 455 shares of the firm's stock in a transaction dated Thursday, February 15th. The shares were purchased at an average price of $222.54 per share, with a total value of $101,255.70. Following the acquisition, the director now owns 20,629 shares of the company's stock, valued at $4,590,777.66. The disclosure for this purchase can be found here. Insiders have sold a total of 882 shares of company stock valued at $202,030 over the last ninety days. 0.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

BIIB has been the subject of several recent analyst reports. BMO Capital Markets cut their price objective on shares of Biogen from $295.00 to $285.00 and set an "outperform" rating for the company in a research report on Wednesday, February 14th. Canaccord Genuity Group reduced their price target on shares of Biogen from $310.00 to $305.00 and set a "buy" rating on the stock in a research report on Tuesday, February 20th. HC Wainwright lowered their price objective on shares of Biogen from $325.00 to $300.00 and set a "buy" rating for the company in a research report on Thursday. Robert W. Baird cut their target price on Biogen from $333.00 to $316.00 and set an "outperform" rating for the company in a research note on Wednesday, February 14th. Finally, Wells Fargo & Company lowered Biogen from an "overweight" rating to an "equal weight" rating and decreased their price target for the company from $315.00 to $240.00 in a research note on Wednesday, February 14th. Ten equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $293.88.

Biogen Trading Up 3.2 %

Shares of NASDAQ:BIIB traded up $6.44 during midday trading on Friday, reaching $208.90. The company's stock had a trading volume of 1,894,098 shares, compared to its average volume of 1,185,437. Biogen Inc. has a fifty-two week low of $189.44 and a fifty-two week high of $319.76. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.26 and a current ratio of 2.10. The firm has a 50 day moving average price of $212.55 and a two-hundred day moving average price of $233.34. The firm has a market capitalization of $30.42 billion, a price-to-earnings ratio of 26.08, a PEG ratio of 2.13 and a beta of -0.02.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Wednesday, April 24th. The biotechnology company reported $3.67 earnings per share for the quarter, topping analysts' consensus estimates of $3.45 by $0.22. The business had revenue of $2.29 billion during the quarter, compared to the consensus estimate of $2.31 billion. Biogen had a return on equity of 14.83% and a net margin of 12.07%. The firm's revenue for the quarter was down 7.0% on a year-over-year basis. During the same period in the previous year, the company posted $3.40 earnings per share. As a group, analysts forecast that Biogen Inc. will post 15.57 earnings per share for the current year.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.